Data gathered: November 27
AI Stock Analysis - Korro Bio (KRRO)
Analysis generated September 18, 2024. Powered by Chat GPT.
Korro Bio, a biotechnology company, specializes in the development and commercialization of innovative RNA editing technologies aimed at treating genetic diseases. The company’s cutting-edge platform leverages the natural machinery of cellular processes, promising a revolution in targeted, durable, and safe genetic medicine. Korro Bio is firmly positioned in the biotech landscape, focusing on making transformative therapeutic approaches to address serious genetic disorders, which gives it a strong foundation in a high-potential sector.
Stock Alerts - Korro Bio (KRRO)
 |
Korro Bio | November 26 Price is up by 5.7% in the last 24h. |
|
Korro Bio | November 22 Price is up by 8.7% in the last 24h. |
|
Korro Bio | November 21 Price is up by 6.2% in the last 24h. |
|
Korro Bio | November 20 Price is up by 6.1% in the last 24h. |
Alternative Data for Korro Bio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 62 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | 6 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,417 | Sign up | Sign up | Sign up |
| Twitter Followers | 447 | Sign up | Sign up | Sign up |
| Twitter Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 32 | Sign up | Sign up | Sign up |
| Linkedin Employees | 105 | Sign up | Sign up | Sign up |
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States.
| Price | $54.99 |
| Target Price | Sign up |
| Volume | 26,390 |
| Market Cap | $487M |
| Year Range | $31.3 - $90 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Korro Bio’s (KRRO) “Buy” Rating Reiterated at HC WainwrightNovember 25 - ETF Daily News |
 |
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Buy” from BrokeragesNovember 22 - ETF Daily News |
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study of KRRO-110 for Alpha-1 Antitrypsin DeficiencyNovember 21 - Finnhub |
|
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin DeficiencyNovember 21 - GlobeNewswire |
|
Korro Bio : Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO 110 for Alpha 1 Antitrypsin Deficiency Form 8 KNovember 20 - Finnhub |
|
|
FY2024 EPS Estimates for Korro Bio Raised by William BlairNovember 18 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 7.3M | -7.3M | -21M | 0 | 0.000 |
| Q2 '24 | 0 | 7M | -7M | -22M | -24M | -2.429 |
| Q1 '24 | 0 | 7.9M | -7.9M | -20M | -21M | -2.440 |
| Q4 '23 | 0 | 8.7M | -11M | -39M | -38M | -25.650 |
| Q3 '23 | 580,000 | 10M | -9.5M | -18M | -12M | -15.500 |
Insider Transactions View All
| Agarwal Vineet filed to sell 7,835 shares at $77. October 18 '24 |
| Agarwal Vineet filed to sell 7,858 shares at $76. October 18 '24 |
| Agarwal Vineet filed to sell 7,914 shares at $74.6. October 18 '24 |
Similar companies
Read more about Korro Bio (KRRO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Korro Bio?
The Market Cap of Korro Bio is $487M.
What is the current stock price of Korro Bio?
Currently, the price of one share of Korro Bio stock is $54.99.
How can I analyze the KRRO stock price chart for investment decisions?
The KRRO stock price chart above provides a comprehensive visual representation of Korro Bio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Korro Bio shares. Our platform offers an up-to-date KRRO stock price chart, along with technical data analysis and alternative data insights.
Does KRRO offer dividends to its shareholders?
As of our latest update, Korro Bio (KRRO) does not offer dividends to its shareholders. Investors interested in Korro Bio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Korro Bio?
Some of the similar stocks of Korro Bio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.